SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT [Yahoo! Finance]
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer [Yahoo! Finance]
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium [Yahoo! Finance]
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium